Ronald J. Halbert
Research Subjects
Ronald J. Halbert has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Sharon Isonaka
Cedars-Sinai Health System, Los Angeles, California, USA
10 shared publicationsRobert J. Nordyke
PriceSpective, Los Angeles, CA
9 shared publicationsGonzalo Valdivia
8 shared publicationsJulio Pertuzé
8 shared publicationsAdriana Muiño
7 shared publicationsCarlos Tálamo
7 shared publications
Latest Publications
- Open Access
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (4) , 572-573
Association of Standardization of Continuous Renal Replacement Therapy and High-Value Care
Continuous renal replacement therapy (CRRT) is an essential tool in the management of renal failure in patients who are critically ill. Though its utilization has increased globally, it is a resource-intensive, costlier modality of dialysis.1-4 Furthermore, its usage is highly variable owing to the heterogeneity of patients and physicians, as well as the paucity of evidence to guide practice.5 These characteristics make it a prime target for high-value care through standardization of practice. At our institution, we assessed utilization patterns of CRRT and established evidence-based guidelines to standardize process flow and promote meaningful use.
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (4) , 572-573
Open AccessAssociation of Standardization of Continuous Renal Replacement Therapy and High-Value Care
Continuous renal replacement therapy (CRRT) is an essential tool in the management of renal failure in patients who are critically ill. Though its utilization has increased globally, it is a resource-intensive, costlier modality of dialysis.1-4 Furthermore, its usage is highly variable owing to the heterogeneity of patients and physicians, as well as the paucity of evidence to guide practice.5 These characteristics make it a prime target for high-value care through standardization of practice. At our institution, we assessed utilization patterns of CRRT and established evidence-based guidelines to standardize process flow and promote meaningful use.
- 4 October 2017
- Published by Wiley in Journal of Hospital Medicine
- Vol. 13 (4) , 229-235
The Enhanced Care Program: Impact of a Care Transition Program on 30‐Day Hospital Readmissions for Patients Discharged From an Acute Care Facility to Skilled Nursing Facilities
BACKGROUND: Increased acuity of skilled nursing facility (SNF) patients challenges the current system of care for these patients.OBJECTIVE: Evaluate the impact on 30‐day readmissions of a program designed to enhance the care of patients discharged from an acute care facility to SNFs.DESIGN: An observational, retrospective cohort analysis of 30‐day hospital readmissions for patients discharged to 8 SNFs between January 1, 2014, and June 30, 2015.SETTING: A collaboration between a large, acute care hospital in an urban setting, an interdisciplinary clinical team, 124 community physicians, and 8 SNFs.PATIENTS: All patients discharged from Cedars‐Sinai Medical Center to 8 partner SNFs were eligible for participation.INTERVENTION: The Enhanced Care Program (ECP) involved the following 3 interventions in addition to standard care: (1) a team of nurse practitioners participating in the care of SNF patients; (2) a pharmacist‐driven medication reconciliation at the time of transfer; and (3) educational in‐services for SNF nursing staff.MEASUREMENT: Thirty‐day readmission rate for ECP patients compared to patients not enrolled in ECP.RESULTS: The average unadjusted, 30‐day readmission rate for ECP patients over the 18‐month study period was 17.2% compared to 23.0% among patients not enrolled in ECP (P < .001). After adjustment for sociodemographic and clinical characteristics, ECP patients had 29% lower odds of being readmitted within 30 days (P < .001). These effects were robust to stratified analyses, analyses adjusted for clustering, and balancing of covariates using propensity weighting.CONCLUSIONS: A coordinated, interdisciplinary team caring for SNF patients can reduce 30‐day hospital readmissions.
- 4 October 2017
- Published by Wiley in Journal of Hospital Medicine
- Vol. 13 (4) , 229-235
The Enhanced Care Program: Impact of a Care Transition Program on 30‐Day Hospital Readmissions for Patients Discharged From an Acute Care Facility to Skilled Nursing Facilities
BACKGROUND: Increased acuity of skilled nursing facility (SNF) patients challenges the current system of care for these patients.OBJECTIVE: Evaluate the impact on 30‐day readmissions of a program designed to enhance the care of patients discharged from an acute care facility to SNFs.DESIGN: An observational, retrospective cohort analysis of 30‐day hospital readmissions for patients discharged to 8 SNFs between January 1, 2014, and June 30, 2015.SETTING: A collaboration between a large, acute care hospital in an urban setting, an interdisciplinary clinical team, 124 community physicians, and 8 SNFs.PATIENTS: All patients discharged from Cedars‐Sinai Medical Center to 8 partner SNFs were eligible for participation.INTERVENTION: The Enhanced Care Program (ECP) involved the following 3 interventions in addition to standard care: (1) a team of nurse practitioners participating in the care of SNF patients; (2) a pharmacist‐driven medication reconciliation at the time of transfer; and (3) educational in‐services for SNF nursing staff.MEASUREMENT: Thirty‐day readmission rate for ECP patients compared to patients not enrolled in ECP.RESULTS: The average unadjusted, 30‐day readmission rate for ECP patients over the 18‐month study period was 17.2% compared to 23.0% among patients not enrolled in ECP (P < .001). After adjustment for sociodemographic and clinical characteristics, ECP patients had 29% lower odds of being readmitted within 30 days (P < .001). These effects were robust to stratified analyses, analyses adjusted for clustering, and balancing of covariates using propensity weighting.CONCLUSIONS: A coordinated, interdisciplinary team caring for SNF patients can reduce 30‐day hospital readmissions.
- 17 March 2017
- Published by Oncology Nursing Society (ONS) in Clinical Journal of Oncology Nursing
- Vol. 21 (2) , E38-E48
Tools for Communication: Novel Infrastructure to Address Patient-Perceived Gaps in Oncology Care
Healthcare providers (HCPs) and patient communication are integral to high-quality oncology care. The patient and HCP perspectives are needed to identify gaps in care and develop communication tools. . This study aimed to understand patient- and HCP-perceived elements of and gaps in high-quality care to develop novel communication tools to improve care. . Qualitative interviews were conducted among 16 patients with cancer and 10 HCPs in the United States. Trained interviewers elicited patients' and HCPs' concerns, views, and perceived needs for communication tools. A thematic analysis was used to identify four quality of care domains, depicted in a conceptual model, and two draft communication tools were developed to address identified gaps. . No patients reported previously using a communication tool, and gaps in communication regarding treatment aims and education were evident. Two tools were developed to assess patients' life and treatment goals and the importance of ongoing education.
- 17 March 2017
- Published by Oncology Nursing Society (ONS) in Clinical Journal of Oncology Nursing
- Vol. 21 (2) , E38-E48
Tools for Communication: Novel Infrastructure to Address Patient-Perceived Gaps in Oncology Care
Healthcare providers (HCPs) and patient communication are integral to high-quality oncology care. The patient and HCP perspectives are needed to identify gaps in care and develop communication tools. . This study aimed to understand patient- and HCP-perceived elements of and gaps in high-quality care to develop novel communication tools to improve care. . Qualitative interviews were conducted among 16 patients with cancer and 10 HCPs in the United States. Trained interviewers elicited patients' and HCPs' concerns, views, and perceived needs for communication tools. A thematic analysis was used to identify four quality of care domains, depicted in a conceptual model, and two draft communication tools were developed to address identified gaps. . No patients reported previously using a communication tool, and gaps in communication regarding treatment aims and education were evident. Two tools were developed to assess patients' life and treatment goals and the importance of ongoing education.
- Open Access
- 1 September 2016
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 8, 495-506
Patient-level costs of major cardiovascular conditions: a review of the international literature
Objective: Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events. Methods: MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest – unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values. Results: Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union. Conclusion: This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed.
- 1 September 2016
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 8, 495-506
Open AccessPatient-level costs of major cardiovascular conditions: a review of the international literature
Objective: Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events. Methods: MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest – unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values. Results: Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union. Conclusion: This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed.
- 1 November 2013
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 49 (11) , 468-474
Comorbilidades y estado de salud en individuos con y sin EPOC en 5 ciudades de América Latina: Estudio PLATINO
- 1 November 2013
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 49 (11) , 468-474
Comorbilidades y estado de salud en individuos con y sin EPOC en 5 ciudades de América Latina: Estudio PLATINO
- 1 December 2012
- Published by Elsevier in Value in Health Regional Issues
- Vol. 1 (2) , 228-234
Potential Regulatory and Commercial Environment for Biosimilars in Latin America
- 1 December 2012
- Published by Elsevier in Value in Health Regional Issues
- Vol. 1 (2) , 228-234
Potential Regulatory and Commercial Environment for Biosimilars in Latin America
- 1 May 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 8 (3S) , 22s-27s
US Payer Perspectives on Evidence for Formulary Decision Making
To improve formulary design processes and support payers in providing more effective health care, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.
- 1 May 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 8 (3S) , 22s-27s
US Payer Perspectives on Evidence for Formulary Decision Making
To improve formulary design processes and support payers in providing more effective health care, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.
- 1 May 2012
- Vol. 18, SP71-6
US payer perspectives on evidence for formulary decision making.
The perspective of commercial payers on comparative effectiveness research (CER) has not been well researched. This study aims to describe how US commercial payers use and value CER for formulary decision making in different disease states. We recruited 20 medical and pharmaceutical directors from national and regional plans who are involved in pharmaceutical and therapeutics committees to participate in the study. We conducted in-depth qualitative interviews with the payers and asked them to rate the usefulness of CER study types across various disease states and market conditions. The results were analyzed for thematic content. Our findings indicate that payers are interested in a broad range of CER study types, are unsatisfied with the current state of CER, and would like to partner with research groups to develop research and treatment guidelines to better leverage CER. Payers value CER less in oncology than in other disease states because of limitations in their ability to manage oncology therapies. To improve formulary design processes and support payers in providing more effective healthcare, policy makers should consider involving commercial payers in the development of CER as well as in the creation of research and treatment guidelines.
- 1 May 2012
- Vol. 18, SP71-6
US payer perspectives on evidence for formulary decision making.
The perspective of commercial payers on comparative effectiveness research (CER) has not been well researched. This study aims to describe how US commercial payers use and value CER for formulary decision making in different disease states. We recruited 20 medical and pharmaceutical directors from national and regional plans who are involved in pharmaceutical and therapeutics committees to participate in the study. We conducted in-depth qualitative interviews with the payers and asked them to rate the usefulness of CER study types across various disease states and market conditions. The results were analyzed for thematic content. Our findings indicate that payers are interested in a broad range of CER study types, are unsatisfied with the current state of CER, and would like to partner with research groups to develop research and treatment guidelines to better leverage CER. Payers value CER less in oncology than in other disease states because of limitations in their ability to manage oncology therapies. To improve formulary design processes and support payers in providing more effective healthcare, policy makers should consider involving commercial payers in the development of CER as well as in the creation of research and treatment guidelines.
- Open Access
- 26 January 2012
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 40 (1) , 28-36
The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study
Little information exists regarding the epidemiology of the chronic bronchitis phenotype in unselected chronic obstructive pulmonary disease (COPD) populations. We examined the prevalence of the chronic bronchitis phenotype in COPD and non-COPD subjects from the PLATINO study, and investigated how it is associated with important outcomes.Post-bronchodilator forced expiratory volume in 1 s/forced vital capacity <0.70 was used to define COPD. Chronic bronchitis was defined as phlegm on most days, at least 3 months per year for ≥2 yrs. We also analysed another definition: cough and phlegm on most days, at least 3 months per year for ≥2 yrs.Spirometry was performed in 5,314 subjects (759 with and 4,554 without COPD). The proportion of subjects with and without COPD with chronic bronchitis defined as phlegm on most days, at least 3 months per year for ≥2 yrs was 14.4 and 6.2%, respectively. Using the other definition the prevalence was lower: 7.4% with and 2.5% without COPD. Among subjects with COPD, those with chronic bronchitis had worse lung function and general health status, and had more respiratory symptoms, physical activity limitation and exacerbations.Our study helps to understand the prevalence of the chronic bronchitis phenotype in an unselected COPD population at a particular time-point and suggests that chronic bronchitis in COPD is possibly associated with worse outcomes.
- 26 January 2012
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 40 (1) , 28-36
Open AccessThe chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study
Little information exists regarding the epidemiology of the chronic bronchitis phenotype in unselected chronic obstructive pulmonary disease (COPD) populations. We examined the prevalence of the chronic bronchitis phenotype in COPD and non-COPD subjects from the PLATINO study, and investigated how it is associated with important outcomes.Post-bronchodilator forced expiratory volume in 1 s/forced vital capacity <0.70 was used to define COPD. Chronic bronchitis was defined as phlegm on most days, at least 3 months per year for ≥2 yrs. We also analysed another definition: cough and phlegm on most days, at least 3 months per year for ≥2 yrs.Spirometry was performed in 5,314 subjects (759 with and 4,554 without COPD). The proportion of subjects with and without COPD with chronic bronchitis defined as phlegm on most days, at least 3 months per year for ≥2 yrs was 14.4 and 6.2%, respectively. Using the other definition the prevalence was lower: 7.4% with and 2.5% without COPD. Among subjects with COPD, those with chronic bronchitis had worse lung function and general health status, and had more respiratory symptoms, physical activity limitation and exacerbations.Our study helps to understand the prevalence of the chronic bronchitis phenotype in an unselected COPD population at a particular time-point and suggests that chronic bronchitis in COPD is possibly associated with worse outcomes.
- 1 September 2011
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 15 (9) , 1259-1264
Paid employment in subjects with and without chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a costly condition that frequently causes permanent work disabilities. Little information exists regarding the impact of COPD on work force participation and the indirect costs of the disease in developing countries. OBJECTIVE: To examine the frequency of paid employment and factors influencing it in a Latin-American population-based study. METHODS: Post-bronchodilator FEV1/FVC < 0.70 (forced expiratory volume in 1 s/forced vital capacity) was used to define COPD. Information regarding paid work was assessed by the question ‘At any time in the past year, have you worked for payment?’ RESULTS: Interviews were conducted with 5571 subjects; 5314 (759 COPD and 4554 non-COPD) subjects underwent spirometry. Among the COPD subjects, 41.8% reported having paid work vs. 57.1% of non-COPD (P < 0.0001). The number of months with paid work was reduced in COPD patients (10.5 ± 0.17 vs. 10.9 ± 0.06, P < 0.05). The main factors associated with having paid work in COPD patients were male sex (OR 0.33, 95%CI 0.23–0.47), higher education level (OR 1.05, 95%CI 1.01–1.09) and younger age (OR 0.90, 95%CI 0.88–0.92). COPD was not a significant contributor to employment (OR 0.83, 95%CI 0.69–1.00, P = 0.054) in the entire population. CONCLUSIONS: Although the proportion of persons with paid work is lower in COPD, having COPD appears not to have a significant impact on obtaining paid employment in the overall population of developing countries.
- 1 September 2011
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 15 (9) , 1259-1264
Paid employment in subjects with and without chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a costly condition that frequently causes permanent work disabilities. Little information exists regarding the impact of COPD on work force participation and the indirect costs of the disease in developing countries. OBJECTIVE: To examine the frequency of paid employment and factors influencing it in a Latin-American population-based study. METHODS: Post-bronchodilator FEV1/FVC < 0.70 (forced expiratory volume in 1 s/forced vital capacity) was used to define COPD. Information regarding paid work was assessed by the question ‘At any time in the past year, have you worked for payment?’ RESULTS: Interviews were conducted with 5571 subjects; 5314 (759 COPD and 4554 non-COPD) subjects underwent spirometry. Among the COPD subjects, 41.8% reported having paid work vs. 57.1% of non-COPD (P < 0.0001). The number of months with paid work was reduced in COPD patients (10.5 ± 0.17 vs. 10.9 ± 0.06, P < 0.05). The main factors associated with having paid work in COPD patients were male sex (OR 0.33, 95%CI 0.23–0.47), higher education level (OR 1.05, 95%CI 1.01–1.09) and younger age (OR 0.90, 95%CI 0.88–0.92). COPD was not a significant contributor to employment (OR 0.83, 95%CI 0.69–1.00, P = 0.054) in the entire population. CONCLUSIONS: Although the proportion of persons with paid work is lower in COPD, having COPD appears not to have a significant impact on obtaining paid employment in the overall population of developing countries.